ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome

Erin M. Parry; Camilla K. Lemvigh; Stephanie Deng; Nathan Dangle; Neil Ruthen; Binyamin A. Knisbacher; Julien Broséus; Sébastien Hergalant; Romain Guièze; Shuqiang Li; Wandi Zhang; Connor Johnson; Jaclyn M. Long; Shanye Yin; Lillian Werner; Annabelle Anandappa; Noelia Purroy; Satyen Gohil; Giacomo Oliveira; Pavan Bachireddy; Sachet A. Shukla; Teddy Huang; Joseph D. Khoury; Beenu Thakral; Michael Dickinson; Constantine Tam; Kenneth J. Livak; Gad Getz; Donna Neuberg; Pierre Feugier; Peter Kharchenko; William Wierda; Lars Rønn Olsen; Nitin Jain; Catherine J. Wu

doi:10.1016/j.ccell.2023.08.013

ZNF683 marks a CD8⁺ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome

Erin M. Parry, Camilla K. Lemvigh, Stephanie Deng, Nathan Dangle, Neil Ruthen, Binyamin A. Knisbacher, Julien Broséus, Sébastien Hergalant, Romain Guièze, Shuqiang Li, Wandi Zhang, Connor Johnson, Jaclyn M. Long, Shanye Yin, Lillian Werner, Annabelle Anandappa, Noelia Purroy, Satyen Gohil, Giacomo Oliveira, Pavan BachireddySachet A. Shukla, Teddy Huang, Joseph D. Khoury, Beenu Thakral, Michael Dickinson, Constantine Tam, Kenneth J. Livak, Gad Getz, Donna Neuberg, Pierre Feugier, Peter Kharchenko, William Wierda, Lars Rønn Olsen, Nitin Jain, Catherine J. Wu^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Unlike many other hematologic malignancies, Richter syndrome (RS), an aggressive B cell lymphoma originating from indolent chronic lymphocytic leukemia, is responsive to PD-1 blockade. To discover the determinants of response, we analyze single-cell transcriptome data generated from 17 bone marrow samples longitudinally collected from 6 patients with RS. Response is associated with intermediate exhausted CD8 effector/effector memory T cells marked by high expression of the transcription factor ZNF683, determined to be evolving from stem-like memory cells and divergent from terminally exhausted cells. This signature overlaps with that of tumor-infiltrating populations from anti-PD-1 responsive solid tumors. ZNF683 is found to directly target key T cell genes (TCF7, LMO2, CD69) and impact pathways of T cell cytotoxicity and activation. Analysis of pre-treatment peripheral blood from 10 independent patients with RS treated with anti-PD-1, as well as patients with solid tumors treated with anti-PD-1, supports an association of ZNF683^high T cells with response.

Original language	English
Journal	Cancer Cell
Volume	41
Issue number	10
Pages (from-to)	1803-1816
ISSN	1535-6108
DOIs	https://doi.org/10.1016/j.ccell.2023.08.013
Publication status	Published - 2023

Access to Document

10.1016/j.ccell.2023.08.013

OpenUrl availability

Full text

Cite this

Parry, E. M., Lemvigh, C. K., Deng, S., Dangle, N., Ruthen, N., Knisbacher, B. A., Broséus, J., Hergalant, S., Guièze, R., Li, S., Zhang, W., Johnson, C., Long, J. M., Yin, S., Werner, L., Anandappa, A., Purroy, N., Gohil, S., Oliveira, G., ... Wu, C. J. (2023). ZNF683 marks a CD8⁺ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer Cell, 41(10), 1803-1816. https://doi.org/10.1016/j.ccell.2023.08.013

@article{16a733b3c01548b284c96f4d02403eb8,

title = "ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome",

abstract = "Unlike many other hematologic malignancies, Richter syndrome (RS), an aggressive B cell lymphoma originating from indolent chronic lymphocytic leukemia, is responsive to PD-1 blockade. To discover the determinants of response, we analyze single-cell transcriptome data generated from 17 bone marrow samples longitudinally collected from 6 patients with RS. Response is associated with intermediate exhausted CD8 effector/effector memory T cells marked by high expression of the transcription factor ZNF683, determined to be evolving from stem-like memory cells and divergent from terminally exhausted cells. This signature overlaps with that of tumor-infiltrating populations from anti-PD-1 responsive solid tumors. ZNF683 is found to directly target key T cell genes (TCF7, LMO2, CD69) and impact pathways of T cell cytotoxicity and activation. Analysis of pre-treatment peripheral blood from 10 independent patients with RS treated with anti-PD-1, as well as patients with solid tumors treated with anti-PD-1, supports an association of ZNF683high T cells with response.",

author = "Parry, {Erin M.} and Lemvigh, {Camilla K.} and Stephanie Deng and Nathan Dangle and Neil Ruthen and Knisbacher, {Binyamin A.} and Julien Bros{\'e}us and S{\'e}bastien Hergalant and Romain Gui{\`e}ze and Shuqiang Li and Wandi Zhang and Connor Johnson and Long, {Jaclyn M.} and Shanye Yin and Lillian Werner and Annabelle Anandappa and Noelia Purroy and Satyen Gohil and Giacomo Oliveira and Pavan Bachireddy and Shukla, {Sachet A.} and Teddy Huang and Khoury, {Joseph D.} and Beenu Thakral and Michael Dickinson and Constantine Tam and Livak, {Kenneth J.} and Gad Getz and Donna Neuberg and Pierre Feugier and Peter Kharchenko and William Wierda and Olsen, {Lars R{\o}nn} and Nitin Jain and Wu, {Catherine J.}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

doi = "10.1016/j.ccell.2023.08.013",

language = "English",

volume = "41",

pages = "1803--1816",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "10",

}

Parry, EM, Lemvigh, CK, Deng, S, Dangle, N, Ruthen, N, Knisbacher, BA, Broséus, J, Hergalant, S, Guièze, R, Li, S, Zhang, W, Johnson, C, Long, JM, Yin, S, Werner, L, Anandappa, A, Purroy, N, Gohil, S, Oliveira, G, Bachireddy, P, Shukla, SA, Huang, T, Khoury, JD, Thakral, B, Dickinson, M, Tam, C, Livak, KJ, Getz, G, Neuberg, D, Feugier, P, Kharchenko, P, Wierda, W, Olsen, LR, Jain, N & Wu, CJ 2023, 'ZNF683 marks a CD8⁺ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome', Cancer Cell, vol. 41, no. 10, pp. 1803-1816. https://doi.org/10.1016/j.ccell.2023.08.013

TY - JOUR

T1 - ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome

AU - Parry, Erin M.

AU - Lemvigh, Camilla K.

AU - Deng, Stephanie

AU - Dangle, Nathan

AU - Ruthen, Neil

AU - Knisbacher, Binyamin A.

AU - Broséus, Julien

AU - Hergalant, Sébastien

AU - Guièze, Romain

AU - Li, Shuqiang

AU - Zhang, Wandi

AU - Johnson, Connor

AU - Long, Jaclyn M.

AU - Yin, Shanye

AU - Werner, Lillian

AU - Anandappa, Annabelle

AU - Purroy, Noelia

AU - Gohil, Satyen

AU - Oliveira, Giacomo

AU - Bachireddy, Pavan

AU - Shukla, Sachet A.

AU - Huang, Teddy

AU - Khoury, Joseph D.

AU - Thakral, Beenu

AU - Dickinson, Michael

AU - Tam, Constantine

AU - Livak, Kenneth J.

AU - Getz, Gad

AU - Neuberg, Donna

AU - Feugier, Pierre

AU - Kharchenko, Peter

AU - Wierda, William

AU - Olsen, Lars Rønn

AU - Jain, Nitin

AU - Wu, Catherine J.

PY - 2023

Y1 - 2023

N2 - Unlike many other hematologic malignancies, Richter syndrome (RS), an aggressive B cell lymphoma originating from indolent chronic lymphocytic leukemia, is responsive to PD-1 blockade. To discover the determinants of response, we analyze single-cell transcriptome data generated from 17 bone marrow samples longitudinally collected from 6 patients with RS. Response is associated with intermediate exhausted CD8 effector/effector memory T cells marked by high expression of the transcription factor ZNF683, determined to be evolving from stem-like memory cells and divergent from terminally exhausted cells. This signature overlaps with that of tumor-infiltrating populations from anti-PD-1 responsive solid tumors. ZNF683 is found to directly target key T cell genes (TCF7, LMO2, CD69) and impact pathways of T cell cytotoxicity and activation. Analysis of pre-treatment peripheral blood from 10 independent patients with RS treated with anti-PD-1, as well as patients with solid tumors treated with anti-PD-1, supports an association of ZNF683high T cells with response.

AB - Unlike many other hematologic malignancies, Richter syndrome (RS), an aggressive B cell lymphoma originating from indolent chronic lymphocytic leukemia, is responsive to PD-1 blockade. To discover the determinants of response, we analyze single-cell transcriptome data generated from 17 bone marrow samples longitudinally collected from 6 patients with RS. Response is associated with intermediate exhausted CD8 effector/effector memory T cells marked by high expression of the transcription factor ZNF683, determined to be evolving from stem-like memory cells and divergent from terminally exhausted cells. This signature overlaps with that of tumor-infiltrating populations from anti-PD-1 responsive solid tumors. ZNF683 is found to directly target key T cell genes (TCF7, LMO2, CD69) and impact pathways of T cell cytotoxicity and activation. Analysis of pre-treatment peripheral blood from 10 independent patients with RS treated with anti-PD-1, as well as patients with solid tumors treated with anti-PD-1, supports an association of ZNF683high T cells with response.

U2 - 10.1016/j.ccell.2023.08.013

DO - 10.1016/j.ccell.2023.08.013

M3 - Journal article

C2 - 37738974

AN - SCOPUS:85173134668

SN - 1535-6108

VL - 41

SP - 1803

EP - 1816

JO - Cancer Cell

JF - Cancer Cell

IS - 10